Search hospitals > New Jersey > Newark

Rutgers New Jersey Medical School

Claim this profile
Newark, New Jersey 07103
Global Leader in Cancer
Global Leader in Human Immunodeficiency Virus Infection
Conducts research for Squamous Cell Carcinoma
Conducts research for Adenocarcinoma
Conducts research for Breast Cancer
194 reported clinical trials
20 medical researchers
Photo of Rutgers New Jersey Medical School in NewarkPhoto of Rutgers New Jersey Medical School in NewarkPhoto of Rutgers New Jersey Medical School in Newark

Summary

Rutgers New Jersey Medical School is a medical facility located in Newark, New Jersey. This center is recognized for care of Cancer, Human Immunodeficiency Virus Infection, Squamous Cell Carcinoma, Adenocarcinoma, Breast Cancer and other specialties. Rutgers New Jersey Medical School is involved with conducting 194 clinical trials across 325 conditions. There are 20 research doctors associated with this hospital, such as Howard S. Hochster, Missak Haigentz, MD, Eugenia Girda, MD, and Coral Omene, MD, PhD.

Area of expertise

1Cancer
Global Leader
Rutgers New Jersey Medical School has run 38 trials for Cancer. Some of their research focus areas include:
Stage III
Stage IV
Stage II
2Human Immunodeficiency Virus Infection
Global Leader
Rutgers New Jersey Medical School has run 34 trials for Human Immunodeficiency Virus Infection.

Top PIs

Clinical Trials running at Rutgers New Jersey Medical School

Breast Cancer
Prostate Cancer
Squamous Cell Carcinoma
Oropharyngeal Carcinoma
Laryngeal Cancer
Cancer
Gallbladder Cancer
Lip and Oral Cavity Cancer
Anal Cancer
Laryngeal Squamous Cell Carcinoma
Image of trial facility.

Chemotherapy Reduction After Surgery

for Breast Cancer

This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Image of trial facility.

Pre-Surgery Radiation Boost

for Breast Cancer

This phase II trial investigates the safety of delivering a part (boost) of radiation treatment before breast surgery in treating patients with breast cancer that has not spread to other places in the body (non-metastatic). Radiation therapy uses high energy photons/electrons to kill tumor cells and shrink tumors. Delivering a boost radiation treatment before surgery when doctors can still visualize the tumor on imaging may help to better target the tumor and decrease the volume of normal irradiated tissue. By so doing, doctors may achieve better cosmetic outcomes and possibly better tumor control.
Recruiting1 award N/A8 criteria
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Rutgers New Jersey Medical School?
Rutgers New Jersey Medical School is a medical facility located in Newark, New Jersey. This center is recognized for care of Cancer, Human Immunodeficiency Virus Infection, Squamous Cell Carcinoma, Adenocarcinoma, Breast Cancer and other specialties. Rutgers New Jersey Medical School is involved with conducting 194 clinical trials across 325 conditions. There are 20 research doctors associated with this hospital, such as Howard S. Hochster, Missak Haigentz, MD, Eugenia Girda, MD, and Coral Omene, MD, PhD.